Vyne Therapeutics INC Form 4 insider transactions

RTW Fund Group GP, LLC and 1 other reported changes in beneficial ownership of VYNE Therapeutics Inc. common stock on July 29, 2026.

Mona Ashiya, a Director of VYNE Therapeutics Inc., received 15,435 shares of common stock on July 27, 2026.

Tyler Zeronda, a Director of VYNE Therapeutics Inc., received 185,798 shares of common stock on July 27, 2026.

Tyler Zeronda, CHIEF FINANCIAL OFFICER of VYNE Therapeutics Inc., reported a transaction in 22,516 shares of common stock on July 23, 2026.

Iain Stuart, CHIEF SCIENTIFIC OFFICER of VYNE Therapeutics Inc., reported a transaction in 15,405 shares of common stock on July 23, 2026.

Mutya Harsch, CHIEF LEGAL OFFICER AND GC of VYNE Therapeutics Inc., reported a transaction in 22,516 shares of common stock on July 23, 2026.

David Domzalski, PRESIDENT AND CEO and a Director of VYNE Therapeutics Inc., reported a transaction in 79,391 shares of common stock on July 23, 2026.

Yarrow Bioscience, Inc. has published an investor presentation detailing its lead drug candidate, YB-101, an anti-TSHR antibody for Graves' Disease and Thyroid Eye Disease, and its planned reverse merger with VYNE Therapeutics.

VYNE Therapeutics announced a special cash dividend of an estimated $16.5 million, or $0.38 per share, in connection with its proposed merger with Yarrow Bioscience.

Tyler Zeronda, Chief Financial Officer of VYNE Therapeutics Inc., reported a transaction involving the acquisition of common stock.

Iain Stuart, Chief Scientific Officer at VYNE Therapeutics Inc., reported a transaction involving the sale of common stock.

Mutya Harsch, Chief Legal Officer of Vyne Therapeutics Inc., reported a transaction involving the withholding of shares for tax purposes.

VYNE Therapeutics Inc. President and CEO David Domzalski reported a disposition of common stock, with shares withheld for tax obligations.

David Domzalski, President and CEO of Vyne Therapeutics Inc., acquired 30,791 shares of common stock through the company's Employee Share Purchase Plan.

VYNE Therapeutics CFO Tyler Zeronda reported the withholding of 4,007 shares to satisfy tax obligations related to RSU vesting.

Chief Scientific Officer Iain Stuart disposed of 2,876 shares of VYNE Therapeutics to satisfy tax obligations related to RSU vesting.

VYNE Therapeutics Inc. amended its merger agreement with Yarrow Bioscience, Inc. to introduce pre-funded warrants, addressing beneficial ownership limitations for Yarrow shareholders.

VYNE Therapeutics Inc. CEO David Domzalski disposed of 12,684 common shares to cover tax withholding related to restricted stock unit vesting.

VYNE Therapeutics Inc.'s Chief Financial Officer, Tyler Zeronda, reported a disposition of 7,858 common shares to cover tax withholding obligations related to restricted stock unit vesting.

VYNE Therapeutics' Chief Scientific Officer, Iain Stuart, disposed of 2,448 shares of common stock to cover tax obligations related to restricted stock unit vesting.

VYNE Therapeutics' Chief Legal Officer, Mutya Harsch, disposed of 3,579 shares of common stock to cover tax obligations related to restricted stock unit vesting.

VYNE Therapeutics and Yarrow Bioscience announced a definitive merger agreement, creating a combined entity focused on advancing Yarrow's lead program, YB-101, for Graves disease and thyroid eye disease, supported by $200 million in pre-closing financings.

VYNE Therapeutics Director Elisabeth Sandoval Little was granted 20,000 stock options as part of her annual non-employee director award.

VYNE Therapeutics Director Patrick G. Lepore was granted 20,000 stock options as part of the annual non-employee director compensation, vesting on December 12, 2026.

VYNE Therapeutics Director Steven L. Basta received an annual award of 20,000 stock options with an exercise price of $0.3756, vesting on December 12, 2026.

VYNE Therapeutics Inc. Director Sharon Barbari was granted 20,000 stock options as part of her annual compensation, vesting in December 2026.

VYNE Therapeutics Inc.'s CFO, Tyler Zeronda, reported a disposition of 3,420 common shares to satisfy tax withholding obligations related to restricted stock unit vesting.

VYNE Therapeutics' Chief Scientific Officer, Stuart Iain, disposed of 2,453 shares of common stock to cover tax obligations related to restricted stock unit vesting.

VYNE Therapeutics' Chief Legal Officer, Mutya Harsch, reported a disposition of 3,581 common shares for tax withholding purposes.

VYNE Therapeutics CEO David Domzalski reported the withholding of 12,676 common shares to cover tax obligations related to restricted stock unit vesting.